Literature DB >> 9309198

Cytokines in juvenile rheumatoid arthritis.

F De Benedetti1, A Ravelli, A Martini.   

Abstract

Most data concerning the role of cytokines in chronic arthritides have been obtained in adult rheumatoid arthritis. In this paper we review the available evidence regarding the role of the inflammatory cytokines interleukin-1, interleukin-6, and tumor necrosis factor in juvenile rheumatoid arthritis, focusing in particular on the differences among the various onset types. Results from the analysis of cytokine expression may provide the basis for the use of specific anticytokine treatment. Recent clinical trials in adult rheumatoid arthritis have demonstrated the feasibility and clinical usefulness of these treatments.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9309198     DOI： 10.1097/00002281-199709000-00009

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN： 1040-8711            Impact factor:   5.006


  9 in total

1.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 2.  Production of interleukin-6 by synovial fibroblasts in rheumatoid arthritis.

Authors:  H Baumann; I Kushner
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

3.  Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).

Authors:  C M Hedrich; N Bruck; B Fiebig; M Gahr
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

4.  Synovial fluid proteins differentiate between the subtypes of juvenile idiopathic arthritis.

Authors:  Margalit E Rosenkranz; David C Wilson; Anthony D Marinov; Alisha Decewicz; Patrick Grof-Tisza; David Kirchner; Brendan Giles; Paul R Reynolds; Michael N Liebman; V S Kumar Kolli; Susan D Thompson; Raphael Hirsch
Journal:  Arthritis Rheum       Date:  2010-06

Review 5.  Biologics in juvenile idiopathic arthritis: a narrative review.

Authors:  Federica Vanoni; Francesca Minoia; Clara Malattia
Journal:  Eur J Pediatr       Date:  2017-07-20       Impact factor: 3.183

6.  Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab.

Authors:  María M Katsicas; Ricardo A G Russo
Journal:  Clin Rheumatol       Date:  2009-03-26       Impact factor: 2.980

7.  The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.

Authors:  H M Walters; N Pan; T J A Lehman; A Adams; G D Kalliolias; Y S Zhu; F Santiago; J Nguyen; L Sitaras; S Cunningham-Rundles; T J Walsh; S S Toussi
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

8.  Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept.

Authors:  Renee F Robinson; Milap C Nahata; John R Hayes; Robert Rennebohm; Gloria Higgins
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

9.  Salivary biomarkers in children with juvenile idiopathic arthritis and healthy age-matched controls: a prospective observational study.

Authors:  Malin Collin; Malin Ernberg; Nikolaos Christidis; Britt Hedenberg-Magnusson
Journal:  Sci Rep       Date:  2022-02-25       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.